Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CAMPBELL'S CoCPB · Entity 3700 | Director | September 29, 2023 | September 29, 2023 |
| COLGATE PALMOLIVE COCL · Entity 2972 | Director | October 01, 2026 | October 03, 2026 |
| Elanco Animal Health IncELAN · Entity 3457 | Director | November 29, 2024 | December 03, 2024 |
| HERSHEY COHSY · Entity 795 | Director | April 01, 2018 | April 03, 2018 |
| TAPESTRY, INC.TPR · Entity 2309 | Director | November 14, 2024 | November 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CAMPBELL'S Co
Report date September 29, 2023 · Filed September 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 22,065.49 |
Reported balance
After 2023-09-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-29 · Grant · Acquired 1,642.03 · Balance 22,065.49 F1: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock. F2: Phantom shares are fully vested. F3: The value of Phantom Stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination. F4: Includes 163.60 shares acquired through dividend reinvestment since the reporting person's last report. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock.
F2: Phantom shares are fully vested.
F3: The value of Phantom Stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination.
F4: Includes 163.60 shares acquired through dividend reinvestment since the reporting person's last report.
COLGATE PALMOLIVE CO
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,725 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 271 · Balance 40,725 F1: Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 4,719 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,719 |
Filing footnotes · ownership attribution and instrument terms
F1: Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors.
Elanco Animal Health Inc
Report date November 29, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,400 |
Reported balance
After 2024-11-29 transaction · row 1
1 source rowRow 1 · 2024-11-29 · Grant · Acquired 18,169 · Balance 78,400 F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 41,722 |
Reported balance
Holding disclosure · report date 2024-11-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 41,722 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.
HERSHEY CO
Report date April 01, 2018 · Filed April 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,148.592 |
Reported balance
After 2018-04-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-04-01 · Grant · Acquired 138.578 · Balance 162,148.592 F1: The total amount of securities reported as directly owned in Column 5 includes 9.716 shares acquired on March 15, 2018, pursuant to a dividend reinvestment feature of the Company's Directors' Compensation Plan, the provisions of which are substantially similar to the dividend reinvestment features of the broad-based dividend reinvestment plan available generally to Company stockholders. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 342.4674 |
Reported balance
Holding disclosure · report date 2018-04-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 342.4674 F2: The total amount of securities reported as indirectly owned by the reporting person includes 1.7996 shares acquired from December 1, 2017 through March 5, 2018, pursuant to the Company's 401(k) Plan ("Plan"). The information is based on a report dated March 6, 2018, provided by the Plan Trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The total amount of securities reported as directly owned in Column 5 includes 9.716 shares acquired on March 15, 2018, pursuant to a dividend reinvestment feature of the Company's Directors' Compensation Plan, the provisions of which are substantially similar to the dividend reinvestment features of the broad-based dividend reinvestment plan available generally to Company stockholders.
F2: The total amount of securities reported as indirectly owned by the reporting person includes 1.7996 shares acquired from December 1, 2017 through March 5, 2018, pursuant to the Company's 401(k) Plan ("Plan"). The information is based on a report dated March 6, 2018, provided by the Plan Trustee.
TAPESTRY, INC.
Report date November 14, 2024 · Filed November 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,846 |
Reported balance
After 2024-11-14 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2024-11-14 · Grant · Acquired 3,459 · Balance 47,846 F1: All of these securities acquired were received in the form of unvested restricted stock units issued under the Issuer's Stock Incentive Plan. These securities will vest on November 14, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 47,846 |
Reported balance
Holding disclosure · report date 2024-11-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 47,846 |
Filing footnotes · ownership attribution and instrument terms
F1: All of these securities acquired were received in the form of unvested restricted stock units issued under the Issuer's Stock Incentive Plan. These securities will vest on November 14, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OLAPLEX HOLDINGS, INC.
Report date July 07, 2026 · Filed July 07, 2026
Section 16 reporting ended · disclosed 2026-07-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-07 transaction · row 1
1 source rowRow 1 · 2026-07-07 · Disposition to issuer · Disposed 640,021 · Balance 0 F2: At the Effective Time, each award of restricted stock units covering Shares granted under the Issuer's 2021 Equity Incentive Plan, the Issuer's Amended & Restated 2020 Omnibus Equity Incentive Plan, or any other effective equity or equity-based incentive plan sponsored by the Issuer or its affiliates (each such award, a "Company RSU Award") that was outstanding immediately prior to the Effective Time (whether vested or unvested) was, by virtue of the Merger, automatically cancelled and converted into the right to receive (without interest) an amount in cash equal to the product of (x) the aggregate number of Shares underlying such Company RSU Award, multiplied by (y) the Merger Consideration. The amount reported includes 294,118 Shares underlying the Reporting Person's Company RSU Awards, which were automatically cancelled and converted into the right to receive the Merger Consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated March 26, 2026, by and among the Issuer, Henkel US Operations Corporation ("Parent"), and Margot Acquisition Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger" and, together with the other transactions contemplated by the Merger Agreement, the "Transactions"). At the effective time of the Merger (the "Effective Time"), each share of Common Stock of the Issuer (each, a "Share") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $2.06 per Share in cash (the "Merger Consideration"), without interest, subject to any withholding of taxes required by applicable law. |
| Common StockSEC Table I · non-derivative | IndirectBy the Amended and Restated John P. Bilbrey Revocable Declaration of Trust | 0 |
Reported balance
After 2026-07-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-07 · Disposition to issuer · Disposed 318,418 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated March 26, 2026, by and among the Issuer, Henkel US Operations Corporation ("Parent"), and Margot Acquisition Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger" and, together with the other transactions contemplated by the Merger Agreement, the "Transactions"). At the effective time of the Merger (the "Effective Time"), each share of Common Stock of the Issuer (each, a "Share") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $2.06 per Share in cash (the "Merger Consideration"), without interest, subject to any withholding of taxes required by applicable law. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated March 26, 2026, by and among the Issuer, Henkel US Operations Corporation ("Parent"), and Margot Acquisition Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger" and, together with the other transactions contemplated by the Merger Agreement, the "Transactions"). At the effective time of the Merger (the "Effective Time"), each share of Common Stock of the Issuer (each, a "Share") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $2.06 per Share in cash (the "Merger Consideration"), without interest, subject to any withholding of taxes required by applicable law.
F2: At the Effective Time, each award of restricted stock units covering Shares granted under the Issuer's 2021 Equity Incentive Plan, the Issuer's Amended & Restated 2020 Omnibus Equity Incentive Plan, or any other effective equity or equity-based incentive plan sponsored by the Issuer or its affiliates (each such award, a "Company RSU Award") that was outstanding immediately prior to the Effective Time (whether vested or unvested) was, by virtue of the Merger, automatically cancelled and converted into the right to receive (without interest) an amount in cash equal to the product of (x) the aggregate number of Shares underlying such Company RSU Award, multiplied by (y) the Merger Consideration. The amount reported includes 294,118 Shares underlying the Reporting Person's Company RSU Awards, which were automatically cancelled and converted into the right to receive the Merger Consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2022 Filed Jan 3, 2023 21:13 UTC | CAMPBELL'S Co CPB · Entity 3700 | GrantPhantom Stock · Derivative | 1,161.61 | $0.00 | $0.00 |
DisclosureSEC source: 0000016732-23-000019 · wf-form4_167278040173970.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,275.36 Underlying: Common Stock · 1,161.61 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock. F2 · derivative.exercise_date: Phantom shares are fully vested. F3 · derivative.expiration_date: The value of phantom stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination. F4 · balance_after: Includes 111.90 shares acquired through dividend reinvestment since the reporting person's last report. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 22:03 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 686.3504 | $12.87 | $8,833.33 |
DisclosureSEC source: 0001415889-22-011971 · form4-12022022_101218.xml · derivative · entry 3 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,764.4903 Underlying: Common Stock · 686.3504 shares Expires not disclosed F2 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F3 · security: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F4 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $12.87 on November 30, 2022. F3 · price: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F4 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $12.87 on November 30, 2022. F2 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 22:03 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 18,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-011971 · form4-12022022_101218.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,857 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 22:52 UTC | TAPESTRY, INC. TPR · Entity 2309 | GrantStock Option · Derivative | 6,822 | $0.00 Strike: $34.98 | $0.00 |
DisclosureSEC source: 0001225208-22-011757 · doc4.xml · derivative · entry 2 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,822 Underlying: Common Stock · 6,822 shares Expires 2032-11-15 F2 · security: All of the securities acquired were issued under the Issuer's Stock Incentive Plan. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 22:52 UTC | TAPESTRY, INC. TPR · Entity 2309 | GrantCommon Stock | 2,430 | $34.98 | $85,001.40 |
DisclosureSEC source: 0001225208-22-011757 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,088 F1 · security: All of the securities acquired were received in the form of unvested restricted stock units issued under the Issuer's Stock Incentive Plan. These securities will vest on November 15, 2023. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 21:40 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 7,500 | $13.24 | $99,267.00 |
DisclosureSEC source: 0001415889-22-011397 · form4-11152022_091113.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Revocable Trust Disclosed balance after: 41,722 F1 · price: Reflects the weighted average price of 7,500 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on November 11, 2022 with purchase prices ranging from $13.22 to $13.27 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 20:32 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 669.699 | $13.19 | $8,833.33 |
DisclosureSEC source: 0001415889-22-011004 · form4-11022022_011109.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,078.1399 Underlying: Common Stock · 669.699 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $13.19 on October 31, 2022. F2 · price: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $13.19 on October 31, 2022. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| October 03, 2022 Filed Oct 6, 2022 00:00 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | GrantCommon Stock | 280 | $75.71 | $21,198.80 |
DisclosureSEC source: 0001225208-22-010844 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,384 F1 · kind: Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:54 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 711.7913 | $12.41 | $8,833.33 |
DisclosureSEC source: 0001415889-22-010281 · form4-10042022_021043.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,408.4409 Underlying: Common Stock · 711.7913 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $12.41 on September 30, 2022. F2 · price: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $12.41 on September 30, 2022. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:14 UTC | CAMPBELL'S Co CPB · Entity 3700 | GrantPhantom Stock · Derivative | 1,401.3 | $0.00 | $0.00 |
DisclosureSEC source: 0000016732-22-000112 · wf-form4_166456888006759.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,001.85 Underlying: Common Stock · 1,401.3 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock. F2 · derivative.exercise_date: Phantom shares are fully vested. F3 · derivative.expiration_date: The value of phantom stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination. F4 · balance_after: Includes 108.15 shares acquired through dividend reinvestment since the reporting person's last report. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 20:05 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 583.8288 | $15.13 | $8,833.33 |
DisclosureSEC source: 0001415889-22-009256 · form4-09022022_010925.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,696.6496 Underlying: Common Stock · 583.8288 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $15.13 on August 31, 2022. F2 · price: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $15.13 on August 31, 2022. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:34 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 435.9985 | $20.26 | $8,833.33 |
DisclosureSEC source: 0001415889-22-008115 · form4-08022022_010800.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,112.8208 Underlying: Common Stock · 435.9985 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $20.26 on July 29, 2022. F2 · price: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $20.26 on July 29, 2022. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 21:05 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | GrantCommon Stock | 273 | $77.62 | $21,190.26 |
DisclosureSEC source: 0001225208-22-008663 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,963 F1 · kind: Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:33 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 449.9913 | $19.63 | $8,833.33 |
DisclosureSEC source: 0001415889-22-007339 · form4-07052022_010732.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,676.8223 Underlying: Common Stock · 449.9913 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $19.63 on June 30, 2022. F2 · price: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $19.63 on June 30, 2022. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| June 29, 2022 Filed Jul 1, 2022 14:19 UTC | CAMPBELL'S Co CPB · Entity 3700 | GrantPhantom Stock · Derivative | 1,361.05 | $0.00 | $0.00 |
DisclosureSEC source: 0000016732-22-000056 · wf-form4_165668517190927.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,492.4 Underlying: Common Stock · 1,361.05 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock. F2 · derivative.exercise_date: Phantom shares are fully vested. F3 · derivative.expiration_date: The value of phantom stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination. F4 · balance_after: Includes 102.78 shares acquired through dividend reinvestment since the reporting person's last report. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 23:53 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 372.7143 | $23.70 | $8,833.33 |
DisclosureSEC source: 0001415889-22-006045 · form4-06022022_040611.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,226.831 Underlying: Common Stock · 372.7143 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $23.70 on May 31, 2022. F2 · price: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $23.70 on May 31, 2022. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| May 11, 2022 Filed May 13, 2022 21:59 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 10,000 | $22.03 | $220,284.00 |
DisclosureSEC source: 0001415889-22-004968 · form4-05132022_020509.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Revocable Trust Disclosed balance after: 34,222 F1 · price: Reflects the weighted average price of 10,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on May 11, 2022 with purchase prices ranging from $21.98 to $22.05 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:32 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | GrantStock Option (Right to Buy) · Derivative | 3,122 | $0.00 Strike: $77.67 | $0.00 |
DisclosureSEC source: 0001225208-22-006880 · doc4.xml · derivative · entry 3 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,122 Underlying: Common Stock · 3,122 shares Expires 2030-05-09 F2 · kind: Annual director stock option grant under the issuer's incentive compensation plan. F3 · derivative.exercise_date: Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 9, 2022 grant date. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:32 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | GrantCommon Stock | 2,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006880 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,565 F1 · kind: Annual director stock grant under the issuer's incentive compensation plan, credited to a stock unit account pursuant to the issuer's incentive compensation plan. Read SEC document |
| April 29, 2022 Filed May 3, 2022 21:30 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 349.0055 | $25.31 | $8,833.33 |
DisclosureSEC source: 0001415889-22-004543 · form4-05032022_020557.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,854.1167 Underlying: Common Stock · 349.0055 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $25.31 on April 29, 2022. F2 · price: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $25.31 on April 29, 2022. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:34 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | GrantCommon Stock | 283 | $75.16 | $21,270.28 |
DisclosureSEC source: 0001225208-22-005405 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,248 F1 · kind: Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:55 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 338.5714 | $26.09 | $8,833.33 |
DisclosureSEC source: 0001415889-22-003756 · form4-04042022_020413.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,505.1112 Underlying: Common Stock · 338.5714 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $26.09 on March 31, 2022. F2 · price: The Deferred Stock Units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $26.09 on March 31, 2022. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:38 UTC | CAMPBELL'S Co CPB · Entity 3700 | GrantPhantom Stock · Derivative | 1,493.76 | $0.00 | $0.00 |
DisclosureSEC source: 0000016732-22-000030 · wf-form4_164884547647523.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,028.56 Underlying: Common Stock · 1,493.76 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock. F2 · derivative.exercise_date: Phantom shares are fully vested. F3 · derivative.expiration_date: The value of phantom stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination. F4 · balance_after: Includes 95.93 shares acquired through dividend reinvestment since the reporting person's last report. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:48 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 310.9233 | $28.41 | $8,833.33 |
DisclosureSEC source: 0001179110-22-001940 · edgar.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,166.5398 Underlying: Common Stock · 310.9233 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $28.41 on February 28, 2022. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $28.41 on February 28, 2022. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 22:29 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,389 | $0.00 Strike: $71.76 | $0.00 |
DisclosureSEC source: 0001225208-22-002185 · doc4.xml · derivative · entry 4 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,389 shares Expires 2022-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options awarded under the issuer's incentive compensation plan. F4 · derivative.exercise_date: Option became exercisable in one-third increments beginning on the first anniversary of the May 9, 2016 grant date. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 22:29 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | SaleCommon Stock | 4,917 | $78.66 | $386,772.70 |
DisclosureSEC source: 0001225208-22-002185 · doc4.xml · nonDerivative · entry 2 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,849 F2 · kind: Sale of shares with proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan. F3 · price: Weighted average price, as these shares were sold in multiple transactions at prices ranging from $78.660 to $78.665, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 22:29 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | Exercise / conversionCommon Stock | 5,389 | $71.76 | $386,714.64 |
DisclosureSEC source: 0001225208-22-002185 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options awarded under the issuer's incentive compensation plan. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:36 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 339.2215 | $26.04 | $8,833.33 |
DisclosureSEC source: 0001179110-22-000723 · edgar.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855.6165 Underlying: Common Stock · 339.2215 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $26.04 on January 31, 2022. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $26.04 on January 31, 2022. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:55 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | GrantCommon Stock | 262 | $81.13 | $21,256.06 |
DisclosureSEC source: 0001225208-22-000481 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,377 F1 · kind: Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:48 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 311.2519 | $28.38 | $8,833.33 |
DisclosureSEC source: 0001179110-22-000131 · edgar.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,516.395 Underlying: Common Stock · 311.2519 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $28.38 on December 31, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $28.38 on December 31, 2021. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 19:59 UTC | CAMPBELL'S Co CPB · Entity 3700 | GrantPhantom Stock · Derivative | 1,524.18 | $0.00 | $0.00 |
DisclosureSEC source: 0000016732-21-000185 · wf-form4_164089434372379.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,438.87 Underlying: Common Stock · 1,524.18 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock. F2 · derivative.exercise_date: Phantom shares are fully vested. F3 · derivative.expiration_date: The value of phantom stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination. F4 · balance_after: Includes 89.96 shares acquired through dividend reinvestment since the reporting person's last report. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:15 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 307.3532 | $28.74 | $8,833.33 |
DisclosureSEC source: 0001179110-21-010539 · edgar.xml · derivative · entry 3 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,205.1431 Underlying: Common Stock · 307.3532 shares Expires not disclosed F2 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F3 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F4 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $28.74 on November 30, 2021. F3 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F4 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $28.74 on November 30, 2021. F2 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:15 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 7,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-010539 · edgar.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,208 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:21 UTC | TAPESTRY, INC. TPR · Entity 2309 | GrantStock Option · Derivative | 5,523 | $0.00 Strike: $41.82 | $0.00 |
DisclosureSEC source: 0001225208-21-013631 · doc4.xml · derivative · entry 2 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,523 Underlying: Common Stock · 5,523 shares Expires 2031-11-03 F2 · security: All of the securities acquired were issued under the Issuer's Stock Incentive Plan. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:21 UTC | TAPESTRY, INC. TPR · Entity 2309 | GrantCommon Stock | 1,793 | $41.82 | $74,983.26 |
DisclosureSEC source: 0001225208-21-013631 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,603 F1 · security: All of the securities acquired were received in the form of unvested restricted stock units issued under the Issuer's Stock Incentive Plan. These securities will vest on November 3, 2022. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:28 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 217.9644 | $32.88 | $7,166.67 |
DisclosureSEC source: 0001179110-21-009767 · edgar.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,897.7899 Underlying: Common Stock · 217.9644 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $32.88 on October 29, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $32.88 on October 29, 2021. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 22:30 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | GrantCommon Stock | 276 | $76.91 | $21,227.16 |
DisclosureSEC source: 0001225208-21-012941 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,997 F1 · kind: Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:20 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 224.731 | $31.89 | $7,166.67 |
DisclosureSEC source: 0001179110-21-009150 · edgar.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,679.8255 Underlying: Common Stock · 224.731 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $31.89 on September 30, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $31.89 on September 30, 2021. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:05 UTC | CAMPBELL'S Co CPB · Entity 3700 | GrantPhantom Stock · Derivative | 1,537.34 | $0.00 | $0.00 |
DisclosureSEC source: 0000016732-21-000109 · wf-form4_163312229284147.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,824.73 Underlying: Common Stock · 1,537.34 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock. F2 · derivative.exercise_date: Phantom shares are fully vested. F3 · derivative.expiration_date: The value of phantom stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination. F4 · balance_after: Includes 70.20 shares acquired through dividend reinvestment since the reporting person's last report. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:25 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 214.6995 | $33.38 | $7,166.67 |
DisclosureSEC source: 0001235110-21-000029 · edgar.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,455.0675 Underlying: Common Stock · 214.6995 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $33.38 on August 31, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $33.38 on August 31, 2021. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 20:43 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 196.5086 | $36.37 | $7,147.02 |
DisclosureSEC source: 0000950138-21-000402 · edgar.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,240.368 Underlying: Common Stock · 196.5086 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $36.37 on July 30, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $36.37 on July 30, 2021. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:28 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | GrantCommon Stock | 258 | $82.33 | $21,241.14 |
DisclosureSEC source: 0001225208-21-010309 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,610 F1 · kind: Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:48 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 206.5918 | $34.69 | $7,166.67 |
DisclosureSEC source: 0000950138-21-000372 · edgar.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,043.8594 Underlying: Common Stock · 206.5918 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $34.69 on June 30, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $34.69 on June 30, 2021. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 20:44 UTC | CAMPBELL'S Co CPB · Entity 3700 | GrantPhantom Stock · Derivative | 1,443.68 | $0.00 | $0.00 |
DisclosureSEC source: 0000016732-21-000079 · wf-form4_162517213767690.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,217.19 Underlying: Common Stock · 1,443.68 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Phantom Stock is the economic equivalent of one share of issuer common stock. F2 · derivative.exercise_date: Phantom shares are fully vested. F3 · derivative.expiration_date: The value of phantom stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination. F4 · balance_after: Includes 51.39 shares acquired through dividend reinvestment since the reporting person's last report. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:50 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 199.1848 | $35.98 | $7,166.67 |
DisclosureSEC source: 0000950138-21-000315 · edgar.xml · derivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,837.2676 Underlying: Common Stock · 199.1848 shares Expires not disclosed F1 · security: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $35.98 on May 28, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $35.98 on May 28, 2021. F1 · derivative.exercise_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Bilbrey elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| May 10, 2021 Filed May 12, 2021 21:03 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | GrantStock Option (Right to Buy) · Derivative | 3,611 | $0.00 Strike: $83.34 | $0.00 |
DisclosureSEC source: 0001225208-21-008044 · doc4.xml · derivative · entry 3 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,611 Underlying: Common Stock · 3,611 shares Expires 2029-05-10 F2 · kind: Annual director stock option grant under the issuer's incentive compensation plan. F3 · derivative.exercise_date: Option becomes exercisable in equal annual installments over three years beginning on the first anniversary of the May 10, 2021 grant date. Read SEC document |
| May 10, 2021 Filed May 12, 2021 21:03 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | GrantCommon Stock | 2,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008044 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,245 F1 · kind: Annual director stock grant under the issuer's incentive compensation plan, credited to a stock unit account pursuant to the issuer's incentive compensation plan. Read SEC document |
| May 05, 2021 Filed May 7, 2021 21:11 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,652 | $0.00 Strike: $67.83 | $0.00 |
DisclosureSEC source: 0001225208-21-007751 · doc4.xml · derivative · entry 4 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,652 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options awarded under the issuer's incentive compensation plan. F3 · derivative.exercise_date: Option became exercisable in one-third increments beginning on the first anniversary of the May 11, 2015 grant date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 21:11 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | SaleCommon Stock | 3,941 | $80.95 | $319,023.95 |
DisclosureSEC source: 0001225208-21-007751 · doc4.xml · nonDerivative · entry 2 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,086 F2 · kind: Sale of shares with proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan. Read SEC document |
| May 05, 2021 Filed May 7, 2021 21:11 UTC | COLGATE PALMOLIVE CO CL · Entity 2972 | Exercise / conversionCommon Stock | 4,652 | $67.83 | $315,545.16 |
DisclosureSEC source: 0001225208-21-007751 · doc4.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options awarded under the issuer's incentive compensation plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.